This activity is designed for hematology/oncology physicians.

After completing this activity, the participant should be better able to:

• Apply current guideline recommendations to differentiate among available treatment options for management of R/R CLL/SLL

• Evaluate current evidence supporting the integration of novel therapies into clinical practice and optimal therapeutic sequencing for patients with R/R CLL/SLL

• Implement current evidence supporting the integration of novel therapies into clinical practice and optimal therapeutic sequencing for patients with R/R CLL/SLL

• Create individualized, evidence-based care plans through shared decision making to overcome barriers in therapeutic sequencing and maximizing the needs and preferences of patients with R/R CLL/SLL

This activity is provided by SOHO & MLI

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute Inc and The Society of Hematologic Oncology. Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS). 

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit. 

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program. 

EBAH Statement

Medical Learning Institute Inc is an accredited CME-CPD provider by the European Board for Accreditation in Hematology (EBAH). 

This educational activity has been submitted to EBAH for review. Final EBAH CME-CPD credits information will be provided to learners prior to the live activity. 

Medical Learning Institute Inc and The Society of Hematologic Oncology are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the activity. 

Faculty Disclosures

Chair/Planner/Presenter
William G. Wierda, MD, PhD
Professor of Medicine
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX, USA

William G. Wierda, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor/Speakers’ Bureau (no compensation): AbbVie, Acerta Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Cyclacel Pharmaceuticals, Intellisphere, Johnson & Johnson, Loxo Oncology, Wiley China
Research Funding/Support (no compensation): AbbVie, Acerta Pharma (a member of the AstraZeneca Group), BeiGene, Bristol Myers Squibb Company, Cyclacel Pharmaceuticals, Genentech (a member of the Roche Group), Gilead Sciences, GlaxoSmithKline, Janssen Biotech, Juno Therapeutics (a Celgene Company), Kite (a Gilead Company), Loxo Oncology (a wholly owned subsidiary of Eli Lilly & Company), Novartis, Oncternal Therapeutics, Numab Therapeutics, Nurix Therapeutics, Pharmacyclics (an AbbVie Company)
Honoraria for educational activities: Clinical Care Targeted Communications, Global learning Collaborative, PSL, Intellisphere, MD Education USA, OncLive, Physicians Education Resource LLC
Other: Supported by the NIH/NCI under award number P30 CA016672 and used MDACC Cancer Center Support Grant (CCSG) shared resources

Planner/Presenter
Catherine C. Coombs, MD
Associate Professor
Division of Hematology-Oncology
Department of Medicine, UCI School of Medicine
Orange, CA, USA

Catherine C. Coombs, MD, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor/Speakers’ Bureau: AbbVie, Allogene (ended), AstraZeneca, BeiGene, Bristol Myers Squibb (ended), Genentech, Janssen (ended), Lilly, Octapharma, Pharmacyclics (ended)
Stock Shares: Pfizer
Research Funding/Support (paid to institution): AbbVie, BeiGene, Carna Bio, Lilly
Honoraria for educational activities (ended): ACHL, Aptitude Health, ASCO Post, Bio Ascend, Cardinal Health, Clinical Care Options, Curio, DAVA Oncology, Dedham Group, IDEOlogy Health, IntrinsiQ, Mashup, Medscape, MJH, MLI, NACE, OncLive, OncoBoard, PER, PeerView, Premier, PRIME, Prova Education, Targeted Oncology

Planner/Presenter
Meghan Thompson, MD
Assistant Attending L1
Memorial Sloane Kettering Cancer Center
New York, NY, USA

Meghan Thompson, MD, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor: AbbVie, AstraZeneca, BeiGene/BeOne, Janssen, Loxo Oncology at Lilly
Research Funding/Support (paid to institution): AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Genentech, GenMab, Nurix Therapeutics
Honoraria for educational activities: Clinical Care Options, Dava Oncology, eScientiq, Mashup Media, MJH Life Sciences, PeerView Medical Institute, Philips Group Oncology Communications, Precisca/Ultimate Opinions in Medicine

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, and The Society of Hematologic Oncology, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity, however, registration is required. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute Inc.

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.

About This Activity

Medical Learning Institute Inc and The Society of Hematologic Oncology are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc and The Society of Hematologic Oncology.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.

Copyright © 2025 Medical Learning Institute Inc.  All Rights Reserved.